Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 3, 2004 - Issue 3
Submit an article Journal homepage
64
Views
5
CrossRef citations to date
0
Altmetric
Review

Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection

Jason E Stout Division of Infectious Diseases, Department of Medicine, Box 3306, Duke University Medical Center, Durham, NC 27710, USA. [email protected]
Pages 187-198 | Published online: 03 Mar 2005

Bibliography

  • CORBETT EL, WATT CJ, WALKER N et al.: The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. (2003) 163:1009–1021.
  • STEAD WW, BATES JH: Evidence of a 'silent' bacillemia in primary tuberculosis. Ann. Intern. Med. (1971) 74:559–561.
  • AMERICAN THORACIC SOCIETY AND CENTERS FOR DISEASE CONTROL AND PRINHEVENTION: Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Grit. Care Med. (2000) 161:S221–S247.
  • ••An excellent basic reference on latent TB.
  • ZEIDBERG LD, GASS RS, DILLON A, HUTCHESON RH: The Williamson County Tuberculosis Study. A twenty-four-year epidemiologic study. Am. Rev Respir. Dis. (1963) 87(3 Pt 2):1–88.
  • PAPE JW, JEAN SS, HO JL, HAFNER A, JOHNSON WD Jr: Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet (1993) 342:268–272.
  • RYAN F: The forgotten plague: how the battle against tuberculosis was won - and lost. Little, Brown & Co., Boston, USA (1992).
  • •A nice historical perspective on TB.
  • FEREBEE SH, MOUNT FW, MURRAY FJ, LIVESAY VT: A controlled trial of isoniazid prophylaxis in mental institutions. Am. Rev Respir. Dis. (1963) 88:161–175.
  • GROTH-PETERSEN E, GAD U, OSTERGAARD F: Mass chemoprophylaxis of tuberculosis. The acceptability and untoward side effects of isoniazid in a control study in Greenland. Am. Rev Respir. Dis. (1960) 81:643–652.
  • FEREBEE SH, MOUNT FW: Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am. Rev Respir. Dis. (1962) 85:490–510.
  • COMSTOCK GW, BAUM C, SNIDER DE Jr: Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies. Am. Rev Respir. Dis. (1979) 119:827–830.
  • BLUMBERG HM, BURIVIAN WJ, CHAISSON RE et al; AMERICAN THORACIC SOCIETY, CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE INFECTIOUS DISEASES SOCIETY: American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. Respir. Grit. Care Med. (2003) 167:603–662.
  • ••The latest US guidelines for treatment ofactive TB.
  • WORLD HEALTH ORGANIZATION: Treatment of tuberculosis: guidelines for national programmes. World Health Organization, Geneva (2003).
  • MERRITT AD, FETTER BF: Toxic hepatic necrosis (hepatitis) due to isoniazid: report of a case with cirrhosis and death due to hemorrhage from esophageal varices. Ann. Intern. Med. (1959) 50:804–810.
  • KOPANOFF DE, SNIDER DE Jr, CARAS GJ: Isoniazid-related hepatitis: a US Public Health Service cooperative surveillance study. Am. Rev Respir. Dis. (1978) 117:991–1001.
  • SALPETER SR: Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West. Med. (1993) 159:560–564.
  • NOLAN CM, GOLDBERG SV, BUSKIN SE: Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. Am. Med. Assoc. (1999) 281:1014–1018.
  • NO AUTHORS LISTED: Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull. World Health Organ. (1982) 60:555–564.
  • ZILTER LA, BAJDAKOVA ZL, GARDAS'JAN AN, KONOVALOV NV, BUNINA TL, BARABADZE ME: The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis. 2. An assessment of the prophylactic effect of pyridoxine in low dosage. Bull. World Health Organ. (1963) 29:457–481.
  • ROTHFIELD NE BIERER WF, GARFIELD JW: Isoniazid induction of antinuclear antibodies. A prospective study. Ann. Intern. Med. (1978) 88:650–652.
  • HOLDINESS MR: Adverse cutaneous reactions to antituberculosis drugs. Int. J. Dermatol (1985) 24:280–285.
  • SNIDER DE Jr, LAYDE PM, JOHNSON MW, LYLE MA: Treatment of tuberculosis during pregnancy. Am. Rev Respir. Dis. (1980) 122:65–79.
  • BOTHAMLEY G: Drug treatment for tuberculosis during pregnancy: safety considerations. Drug Sal (2001) 24:553–565.
  • CZEIZEL AE, ROCKENBAUER M, OLSEN J, SORENSEN HT: A population-based case-control study of the safety of oral anti-tuberculosis drug treatment during pregnancy. Int.j Tuberc. Lung Dis. (2001) 5:564–568.
  • FRANKS AL, BINKIN NJ, SNIDER DE Jr, ROKAW WM, BECKER S: Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep. (1989) 104:151–155.
  • STEELE MA, BURK RF, DESPREZ RM: Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest (1991) 99:465–471.
  • VILLARINO ME, RIDZON R, WEISMULLER PC et al.: Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am.Respir. Crit. Care Med. (1997)155:1735–1738.
  • POLESKY A, FARBER HW, GOTTLIEB DJet al.: Rifampin preventive therapy for tuberculosis in Boston's homeless. Am.). Respir. Crit. Care Med. (1996) 154:1473–1477.
  • NO AUTHORS LISTED: A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am. Rev Respir. Dis. (1992) 145:36–41.
  • SCHABERG T, REBHAN K, LODE H: Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Ear: Respir. (1996) 9:2026–2030.
  • YEE D, VALIQUETTE C, PELLETIER M et al.: Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am.Respic Crit. Care Med. (2003)167:1472–1477.
  • MARTINEZ E, COLLAZOS J, MAYO J: Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore) (1999) 78:361–369.
  • DUTT AK, MOERS D, STEAD WW: Undesirable side effects of isoniazid and rifampin in largely twice-weekly short-course chemotherapy for tuberculosis. Am. Rev Respir. Dis. (1983) 128:419–424.
  • POOLE G, STRADLING P, WORLLEDGE S: Potentially serious side effects of high-dose twice-weekly rifampicin. Br. Med. J. (1971) 3:343–347.
  • PEREIRA J, HIDALGO P, OCQUETEAU M et al: Glycoprotein Ib/IX complex is the target in rifampicin-induced immune thrombocytopenia. Br. Haematol (2000) 110:907–910.
  • STEELE MA, DES PREZ RM: The role of pyrazinamide in tuberculosis chemotherapy. Chest (1988) 94:845–850.
  • ZHANG Y, MITCHISON D: The curious characteristics of pyrazinamide: a review. hat. Tuberc. Lung Dis. (2003) 7:6–21.
  • •A nice review of pyrazinamide.
  • CAMPAGNA M, CALIX A, HAUSER G: Observations on the combined use of pyrazinamide (Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study. Am. Rev Tuberc. (1954) 69:334–350.
  • MCDERMOTT W, ORMOND L, MUSCHENHEIM C et al.: Pyrazinamide-isoniazid in tuberculosis. Am. Rev Tuberc. (1954) 69:319–333.
  • COMBS DL, O'BRIEN RJ, GETTER LJ:USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann. Intern. Med. (1990) 112:397–406.
  • •Classic study that established a 'short-course' 6-month regimen for the treatment of active TB.
  • NO AUTHORS LISTED: Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Joint Tuberculosis Committee of the British Thoracic Society. Thorax (2000) 55:887–901.
  • ••British Thoracic Society Guidelines forTB control.
  • RIEDER HL; INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE: Interventions for tuberculosis control and elimination. International Union Against Tuberculosis and Lung Disease, Paris, France (2002)
  • ••IUATLD guidelines for TB control.
  • BUCHER HC, GRIFFITH LE, GUYATT GH et al.: Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS(1999) 13:501–507.
  • WHALEN CC, JOHNSON JL, OKWERA A et al.: A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N. Engl. .1. Med. (1997) 337:801–808.
  • •Important randomised, placebo-controlled study comparing INH, INH + rifampin, and INH + rifampin + pyrazinamide for latent TB in Uganda.
  • ORMEROD LP: Rifampicin and isoniazidprophylactic chemotherapy for tuberculosis. Arch. Dis. Child. (1998) 78:169–171.
  • MCNAB BD, MARCINIUK DD, ALVI RA, TAN L, HOEPPNER VH: Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian plains Aborigines. Am. J. Respir. Grit. Care Med. (2000) 162:989–993.
  • LECOEUR HF, TRUFFOT-PERNOT C, GROSSET JH: Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am. Rev. Respir. Dis. (1989) 140:1189–1193.
  • HALSEY NA, COBERLY JS, DESORMEAUX Jet al.: Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet (1998) 351:786–792.
  • •Key study of rifampin/pyrazinamide for latent TB in HIV-seropositive patients.
  • GORDIN F, CHAISSON RE, MATTS JP et al.: Rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. j Am. Med. Assoc. (2000) 283:1445–1450.
  • •Key study of rifampin/pyrazinamide for latent TB in HIV-seropositive patients.
  • NO AUTHORS LISTED: Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection - New York and Georgia, 2000. MMWR Morb. Mortal. Wkly. Rep. (2001) 50:289–291.
  • •First case reports of severe hepatitis and death associated with 2RZ.
  • NO AUTHORS LISTED: Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/ CDC recommendations - United States, 2001. MMWR Morb. Mortal. Wkly. Rep. (2001) 50:733–735.
  • NO AUTHORS LISTED: Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb. Mortal. Wkly. Rep. (2002) 51:998–999.
  • MEDINGER A: Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis. Chest (2002) 121: 1710-1712.
  • BOCK NN, ROGERS T, TAPIA JR et al.: Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. Chest (2001) 119:833–837.
  • CHAISSON RE, ARMSTRONG J, STAFFORD J, GOLUB J, BUR S: Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners. Am. Med. Assoc. (2002) 288:165–166.
  • JASMER RM, SAUKKONEN JJ, BLUMBERG HM et al.: Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann. Intern. Med. (2002) 137:640–647.
  • ••Only controlled trial of 2RZ amongpredominantly HIV-seronegative patients.
  • LEE AM, MENN ONE JZ, JONES RC, PAUL WS: Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int. J Tuberc. Lung Dis. (2002) 6:995–1000.
  • MCNEILL L, ALLEN M, ESTRADA C, COOK P: Pyrazinamide and rifampin versus isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest (2003) 123:102–106.
  • STOUT JE, ENGEMANN JJ, CHENG AC, FORTENBERRY ER, HAMILTON CD: Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am. Respir. Crit. Care Med. (2003) 167:824–827.
  • NARITA M, KELLMAN M, FRANCHINI DL et al: Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida. Chest (2002) 122:1292–1298.
  • NO AUTHORS LISTED: Update: adverse event data and revised American Thoracic Society/ CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb. Mortal. Wkly Rep. (2003) 52:735–739.
  • •Most recent US recommendations for use of rifampin/pyrazinamide for latent TB.
  • MILLARD PS, WILCOSKY TC, READE- CHRISTOPHERSJ, WEBER DJ: Isoniazid-related fatal hepatitis. West. J. Med. (1996) 164:486–491.
  • SINGAPORE TUBERCULOSIS SERVICE AND BRITISH MEDICAL RESEARCH COUNCIL: Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am. Rev. Respir. Dis. (1979) 119:579–585.
  • VAN DEN BRANDE P, VAN STEENBERGEN W, VERVOORT G, DEMEDTS M: Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am. J. Respir. Grit. Care Med. (1995) 152:1705–1708.
  • MWINGA A, HOSP M, GODFREY-FAUSSETT P et al.: Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS (1998) 12:2447–2457.
  • GUST ID: Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut (1996) 38\(Suppl. 2):518–523.
  • KLINKENBERG WD, CASLYN RJ, MORSE GA et al.: Prevalence of human immunodeficiency virus, hepatitis B, and hepatitis C among homeless persons with co-occurring severe mental illness and substance use disorders. Compr. Psychiatry (2003) 44:293–302.
  • PATEL PA, VOIGT MD: Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am. Gastroenterol (2002) 97:1198–1203.
  • WU JC, LEE SD, YEH PF et al: Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology (1990) 98:502–504.
  • SADAPHAL P, ASTEMBORSKI J, GRAHAM NM et al.: Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis Clin. Infect. Dis. (2001) 33:1687–1691.
  • ROSE DN: Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis. Ann. Intern. Med. (1998) 129:779–786.
  • TULSKY JP, PILOTE L, HAHN JA et al: Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. Arch. Intern. Med. (2000) 160:697–702.
  • BOCK NN, METZGER BS, TAPIA JR, BLUMBERG HM: A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am. I Respir. Crit. Care Med. (1999) 159:295–300.
  • MCELROY PD, SOUTHWICK KL, FORTENBERRY ER et al.: Outbreak of tuberculosis among homeless persons coinfected with human immunodeficiency virus. Clin. Infect. Dis. (2003) 36:1305–1312.
  • KHAN K, MUENNIG P, BEHTA M, ZIVIN JG: Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N. Engl. J. Med. (2002) 347:1850–1859.

Websites

  • http://www.cdc.gov/nchstp/tb/pubs/ corecurr/default.htm Core Curriculum on Tuberculosis (2000) (2003).
  • ••An overview of TB and US guidelinesfor treatment.
  • http://www.cdc.gov/nchstp/tb/tbtc/ projects.htm Tuberculosis Trials Consortium (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.